



## Daclizumab

Revised: December 3, 2018.

CASRN: 152923-56-3

## Drug Levels and Effects

### Summary of Use during Lactation

No information is available on the clinical use of daclizumab during breastfeeding. Because daclizumab is a large protein molecule with a molecular weight of about 144,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, daclizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Some authors recommend avoiding breastfeeding with daclizumab.[1][2]

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

### Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

### Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

### Alternate Drugs to Consider

(Multiple Sclerosis) Glatiramer, Immune Globulin, Interferon Beta

### References

1. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. *Mult Scler.* 2013;19:835-43. PubMed PMID: 23319073.
2. Almas S, Vance J, Baker T et al. Management of multiple sclerosis in the breastfeeding mother. *Mult Scler Int.* 2016;2016:6527458. PubMed PMID: 26966579.

## Substance Identification

### Substance Name

Daclizumab

### CAS Registry Number

152923-56-3

### Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal, Humanized